CytomX Therapeutics
CTMX
119 hedge funds and large institutions have $299M invested in CytomX Therapeutics in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 17 closing their positions.
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
13% more capital invested
Capital invested by funds: $264M → $299M (+$34.7M)
5% more funds holding
Funds holding: 113 → 119 (+6)
0.33% more ownership
Funds ownership: 78.92% → 79.25% (+0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$6.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.86M |
| 3 |
Renaissance Technologies
New York
|
+$3.58M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$3.26M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$27.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.2M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$7.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.72M |
| 5 |
SIM
Spark Investment Management
New York
|
-$901K |
CTMX Hedge Fund Activity: Q4 2019 in Review
119 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2019, worth a combined $299M — up 13% from $264M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CTMX positions and 17 closed out — a net gain of 6 holders — while 44 added to existing stakes and 35 trimmed.
The largest buyer was First Manhattan, opening a new position worth an estimated $6.6M. The largest seller was Wellington Management Group, cutting an estimated $27.5M.
- 119 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2019, up from 113 in Q3 2019.
- Funds reported $299M of CytomX Therapeutics stock for Q4 2019, up 13% quarter-over-quarter.
- 23 funds opened new CytomX Therapeutics positions in Q4 2019 and 17 closed out, a net change of +6 holders.
- The largest CytomX Therapeutics buyer in Q4 2019 was First Manhattan, an estimated $6.6M added.
- The largest CytomX Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $27.5M sold.
Based on aggregated 13F filings for Q4 2019.